Arun Menawat, CEO of Profound Medical (NASDAQ:PROF; TSX:PRN), was one of three nominees for the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative...
Capricor Therapeutics (NASDAQ:CAPR) reported that all six critical COVID-19 patients who were treated with CAP-1002, an allogeneic cardiac cell therapy, have survived. The six COVID-19 patients, who were admitted to...
ERYTECH Pharma’s (NASDAQ:ERYP) eryaspase received FDA fast track designation for the second-line treatment of patients with metastatic pancreatic cancer. Eryaspase is being evaluated in a Phase 3 trial, called TRYbeCA...
BioXcel Therapeutics (NASDAQ:BTAI) initiated the Phase 2 efficacy portion of its Phase 1b/2 trial of BXCL701, in combination with pembrolizumab, an immunotherapy, for treatment emergent neuroendocrine prostate cancer...
iBio (NYSE AMERICAN:IBIO) estimates that its FastPharming facility could manufacture some 500 million doses of COVID-19 vaccine annually. “If our own proprietary SARS-CoV-2 virus-like particle (VLP) program, IBIO-200...
Axsome Therapeutics’ (NASDAQ:AXSM) AXS-05 met its primary endpoint in a Phase 2/3 trial, called ADVANCE-1, in patients with Alzheimer’s disease (AD)-related agitation. The trial assessed 366 AD patients who were...
Avadel Pharmaceuticals (NASDAQ:AVDL) reported positive topline data from its Phase 3 trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called...
ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), submitted an IND application to the FDA to conduct a Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is a...
Mesoblast (NASDAQ:MESO; ASX:MSB) reported an 83% survival in 10-of-12, or 83%, of ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during March-April 2020...
Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) vixarelimab met its primary efficacy endpoint in Phase 2a trial in patients with prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...